Triptorelin Acetate 3.75mg intramuscular injection
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Deep Infiltrating Endometriosis (DIE)
Conditions
Deep Infiltrating Endometriosis (DIE)
Trial Timeline
Sep 16, 2013 → Jul 13, 2018
NCT ID
NCT01942369About Triptorelin Acetate 3.75mg intramuscular injection
Triptorelin Acetate 3.75mg intramuscular injection is a pre-clinical stage product being developed by Ipsen for Deep Infiltrating Endometriosis (DIE). The current trial status is completed. This product is registered under clinical trial identifier NCT01942369. Target conditions include Deep Infiltrating Endometriosis (DIE).
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01942369 | Pre-clinical | Completed |
Competing Products
20 competing products in Deep Infiltrating Endometriosis (DIE)